US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
イギリス
LSE
Vitura (0DYT) 銘柄情報

Vitura (0DYT)

39.40

0.00

(0.00%)

終了 7月11日 12:30AM

Vitura (0DYT) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

39.40

( - )

買値

39.40

売値

39.40

出来高

0.00

平均取引量 (3 か月)

78 €

財務取引量

-

0.00 日の範囲 0.00

39.40 52 週間の範囲 39.40

時価総額

企業価値

657.767M

前日終値

39.40

始値

-

時刻

最終取引時間

VWAP

-

歳入

58.04M

純利益

-20.76M

発行済株式数

17,047,950

浮動株比率 (%)

16.77%

機関投資家保有比率 (%)

93.39%

配当利回り

PER

-3.2

株価売上高倍率 (PSR)

1.15

1 株当たり利益 (EPS)

-1.22

ベータ

0.54

Vitura SA is a listed real estate company that invests in prime office properties in Paris and Greater Paris. The total value of the portfolio was estimated at 872 million at June 30, 2025 (excluding transfer duties). Thanks to its strong commitment to sustainable development, the Company's leadersh... Vitura SA is a listed real estate company that invests in prime office properties in Paris and Greater Paris. The total value of the portfolio was estimated at 872 million at June 30, 2025 (excluding transfer duties). Thanks to its strong commitment to sustainable development, the Company's leadership position is recognized by ESG rating agencies. Vitura ranks among the top 20% of the 2025 GRESB ranking and has been ranked Global Sector Leader four times. It has also received two Gold Awards from the European Public Real Estate Association (EPRA) for the quality and transparency of its financial and non-financial reporting. Vitura is a REIT listed on Euronext Paris since 2006. Vitura SA was incorporated in 1999 in France. 詳細を表示

セクター

Real Estate

業界

Office Reits

ウェブサイト

www.vitura.fr

本社

Paris, France

設立

1999

Vitura is listed in the Real Estate sector of the ロンドン証券取引所 with ticker 0DYT. The last closing price for Vitura was 39.40 €. Over the last year, Vitura shares have traded in a share price range of 39.40 € to 39.40 €.

Vitura currently has 17,047,950 shares in issue. The market capitalisation of Vitura is 671.69 € million. Vitura has a price to earnings ratio (PE ratio) of -3.20.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	39.4	39.4	39.4	0	0	DE
52	0	0	39.4	39.4	39.4	0	0	DE
156	0	0	39.4	39.4	39.4	0	0	DE
260	0	0	39.4	39.4	39.4	0	39.4	DE

0DYT - Frequently Asked Questions (FAQ)

What is the current Vitura share price?

The current share price of Vitura is 39.40 €

How many Vitura shares are in issue?

Vitura has 17,047,950 shares in issue

What is the market cap of Vitura?

The market capitalisation of Vitura is EUR 671.69M

What is the 1 year trading range for Vitura share price?

Vitura has traded in the range of 39.40 € to 39.40 € during the past year

What is the PE ratio of Vitura?

The price to earnings ratio of Vitura is -3.2

What is the cash to sales ratio of Vitura?

The cash to sales ratio of Vitura is 1.15

What is the registered address of Vitura?

The registered address for Vitura is 42, rue de Bassano, Paris, Ile-de-France, 75008

What is the Vitura website address?

The website address for Vitura is www.vitura.fr

Which industry sector does Vitura operate in?

Vitura operates in the Office REITs sector

BahamaPete

BahamaPete 5分前

Thanks OCKHAM's RAZOR, I added your links to my DD post. Go $TKOI

Helter Skelter

Helter Skelter 14分前

😆 "accurately captures one of the most critical underappreciated alliances..."

https://investorshub.advfn.com/uimage/uploads/2026/7/10/opnhmBB_Can_u_say_MONOPOLY_071026.png

🤑 $BB Where Nvidia Goes We Go $NVDA 🤑

Twiggs333

Twiggs333 21分前

CMPS Compass Pathways: A Structural Mispricing in Plain Sight?

Extremely good explanation of the value of this company by a Stanford Professor.

https://x.com/kevin__mak/status/2075541715272790373

Popeye

Popeye 22分前

Yeah, agreed. That was a shot of the dark guess of the discount for the Reg A and .08 would certainly move the numbers in the favor of the shareholder.
Unknowns are 1. What will the discount be and 2. How much will Korenko raise? (Doesn’t have to raise the entire $9 million now - maybe raise

Twiggs333

Twiggs333 23分前

Compass Pathways: A Structural Mispricing in Plain Sight?

https://x.com/kevin__mak/status/2075541715272790373

CA Market News

CA Market News 27分前

Lion One Announces Closing of Second Tranche of Non-Brokered Private Placement of Convertible Debenture Units and Units for Aggregate Gross Proceeds of $17.5 MillionJuly 10, 2026 11:14 PM
Newsfile

Genz2

Sorry, misspelled Greg’s last name in the previous post!!! It should be Kazmierczak!!

Gus1212

Gus1212 36分前

If this rejection theory is correct, I believe it was just a tactic to stall our approval process.
Sounds too simple, doesn't it!

Maybe paid for by you know who, big pharma.

They all know that DCVAX works; they are not dummies.
Why did they stall? Cou

Whalatane

Whalatane 46分前

A Fable 5 analysis
Synthesized FDA timeline risks, TDAPA reimbursement implications, and dilution concernsSynthesized FDA timeline risks, TDAPA reimbursement implications, and dilution concernsGood context to layer in.
Here's the deeper risk breakdown on those three fronts.

LTR

I think a suitable punishment for these guys would be to lock them up in ILT's vault and throw away the key.

Real McCoy

Real McCoy 52分前

Well yeah this one has the most lies.

3rd attempt: you ok with lies, yes or no?

pos_stock_hoarder

pos_stock_hoarder 54分前

New York Dolls - Looking for a Kiss

https://youtu.be/GvmvMFXWzc8

Genz2

https://techcrunch.com/2026/07/10/us-cyber-agency-cisa-had-to-build-its-incident-playbook-during-the-incident-agency-reveals/

According to Krebs, the researcher tried to alert the contractor but didn’t hear back. Only after Krebs contacted CISA did the agency take the repository offli

boston127

boston127 55分前

Hey,

Thanks for the links you sent me. My PC blocked all of the URLs due to malware protection. I'm still in GNIS and the other one. I was up but they have dive bombed quite rapidly. Now, in the RED. Both companies are interesting.

LTR

I have an idea AF may turn up in discovery when the dots are lined up and connected. AF may look to be a witness in order to avoid being a defendent.

conix

Non-promotional information until there is a press release is a wise move.

CatfishHunter

CatfishHunter 58分前

We should have news of next step well before years end. Vivos is already approved by FDA to start the EFS. Mayo Clinic needs to review and sign off on the approved conditions for the IRB and that’s just a formality. EFS could start as early as August. And 30 day patient status report about 45 days a

Philosophical Trader

Philosophical Trader 58分前

How is this doing? This was a great runner with a 2 year cup and handle.

nwtf

You really dont have a clue what you are talking about. Just stop.

rakp

rakp 1時間前

What do you think BB? Are there any official OTCMarkets notifications/filings and what's this CCLX price of .50 cents? This looks to good to be true.

Doc logic

Doc logic 1時間前

Galzus Research,

What if the end game is a friendly or two to the shorts were to bid for control at the lowest price possible before full Flaskworks validation or the value of Direct can be fully factored in by most investors while NWBO is still on the OTC? Just wondering. Best wish

ace65

ace65 1時間前

WOW...game changer!!Thanks for sharing

nwtf

nwtf 1時間前

LOL LOL LOL LOL

IOW they didnt offer the money they wanted.

Vontobel Financial Produ...

Fundo Invest Imobiliario...

1.500% Nts 06/26/2029 144a

3250% until 10/05/2032 3...

maturity dt 3oct2028

Govsrilanka 24s

Schneider National

Nts Lkd Uksed3p Srs 2746...

Flt Rte Grn Nts 19/03/34

Btp Fx 3.45% Jul31 Eur

MAPtelligent (EM)

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。